EUVIMEDEUVIMED entdecken
Crossref

A novel triazole–dithiocarbamate hybrid synergistically enhances cytarabine efficacy and selectivity in anaplastic large cell lymphoma

Heba F Ashour, Asmaa S A Yassen, Khalid B Selim, Magda A A El-Sayed, Ahmed T Elhendawy, Hosam A Elshihawy

Bioorganic Chemistry · 2026-08 · 178 · 109972

DOI: 10.1016/j.bioorg.2026.109972 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-08. Verfasst von Heba F Ashour und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt; Department of Medicinal Chemistry,…. Hauptthemen laut MEDLINE: Triazoles, Antineoplastic Agents, Lymphoma, Large-Cell, Anaplastic, Cytarabine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 149 Literaturangaben. Gefördert von: Universität zu Lübeck, National Cancer Institute, Minia University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic efficacy of cytarabine (Ara-C) in anaplastic large cell lymphoma (ALCL) is frequently compromised by dose-limiting myelosuppression and drug resistance. To address this, we developed a series of novel 1,2,3-triazole-dithiocarbamate hybrids designed to target Aurora A kinase and enhance chemosensitivity to Ara-C. Compound 22h emerged as the lead candidate, exhibiting potent Aurora A inhibition (IC₅₀ = 0.296 μM) with threefold preferential inhibition over Aurora B (IC₅₀ = 0.887 μM) and sub-micromolar activity against ALK (IC₅₀ = 0.332 μM). Molecular docking and 100-ns molecular dynamics simulations suggest that 22h engages a putative allosteric pocket in Aurora A, centered on Cys290 (S-score -13.67 kcal/mol), conferring superior stability over ATP-site binding, while simultaneously forming stable interactions within the ALK hinge region. In ALK+ ALCL SR cells, 22h demonstrated significant cytotoxicity (IC₅₀ = 5.10 μM) and high tumor selectivity (SI = 7.0) relative to normal peripheral blood mononuclear cells. Mechanistically, 22h induced potent G₂/M arrest (3.2-fold increase), supporting Aurora A as the primary functional target, alongside cellular ALK depletion as a complementary mechanism. Furthermore, it triggered mitochondrial apoptosis (17.8% total apoptotic fraction) and dismantled chemoresistance pathways by elevating intracellular ROS (3.5-fold) and inhibiting ALDH1 activity (IC₅₀ = 2.8 μg/mL). Crucially, co-treatment with 22h synergistically potentiated Ara-C efficacy (Combination Index = 0.78), reducing the Ara-C IC₅₀ by 12.8-fold (from 27.65 μM to 2.15 μM) and dramatically widening the therapeutic window by 14-fold (SI = 29.6). These findings identify 22h as a novel multi-target scaffold with potent Aurora A/ALK inhibitory activity that restores Ara-C sensitivity in ALCL, supporting its further development as a precision chemosensitizer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazolesAntineoplastic AgentsLymphoma, Large-Cell, AnaplasticCytarabineThiocarbamatesProtein Kinase InhibitorsHumansAurora Kinase ADrug Screening Assays, AntitumorStructure-Activity RelationshipCell Line, TumorDose-Response Relationship, DrugCell ProliferationApoptosisMolecular Docking SimulationMolecular StructureDrug Synergism

Stichwörter der Autor:innen

1,2,3-TriazoleAnaplastic large cell lymphoma (ALCL)Anaplastic lymphoma kinase (ALK)Aurora A kinaseChemosensitizerCytarabine (Ara-C)DithiocarbamateMulti-target inhibitor

Substanzen

TriazolesAntineoplastic AgentsCytarabineAurora Kinase AThiocarbamatesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt; Department of Medicinal Chemistry, Faculty of Pharmacy, Galala University, New Galala 43713, Egypt.
  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt; Department of Medicinal Chemistry, Faculty of Pharmacy, Galala University, New Galala 43713, Egypt. Elec…
  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura National University, Gamasa…
  • Physics Department, Faculty of Science, Galala University, New Galala 43713, Egypt.
  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt.

Förderung

  • Universität zu Lübeck
  • National Cancer Institute
  • Minia University

Zitieren

APA

Ashour, H. F., Yassen, A. S. A., Selim, K. B., El-Sayed, M. A. A., Elhendawy, A. T., & Elshihawy, H. A. (2026). A novel triazole–dithiocarbamate hybrid synergistically enhances cytarabine efficacy and selectivity in anaplastic large cell lymphoma. Bioorganic Chemistry, 178, 109972. https://doi.org/10.1016/j.bioorg.2026.109972

Vancouver

Ashour HF, Yassen ASA, Selim KB, El-Sayed MAA, Elhendawy AT, Elshihawy HA. A novel triazole–dithiocarbamate hybrid synergistically enhances cytarabine efficacy and selectivity in anaplastic large cell lymphoma. Bioorganic Chemistry. 2026;178:109972. doi:10.1016/j.bioorg.2026.109972

BibTeX
@article{Ashour2026,
  author = {Ashour, Heba F and Yassen, Asmaa S A and Selim, Khalid B and El-Sayed, Magda A A and Elhendawy, Ahmed T and Elshihawy, Hosam A},
  title = {A novel triazole–dithiocarbamate hybrid synergistically enhances cytarabine efficacy and selectivity in anaplastic large cell lymphoma},
  journal = {Bioorganic Chemistry},
  year = {2026},
  volume = {178},
  pages = {109972},
  doi = {10.1016/j.bioorg.2026.109972}
}
Kostenlos starten →